Clinical Trial

An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
A Phase I/ II, open-label study, designed to evaluate the safety and explore efficacy of the study drug in development for the treatment of MPS IIIB patients.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-06-28; most recent amendment 2025-08-25.
Status change: Not Yet Recruiting → Recruiting 2025-02-03
Trial Details
NCT Number NCT06488924
Lead Sponsor JCR Pharmaceuticals Co., Ltd.
Conditions Mucopolysaccharidosis III-B
Enrollment 10 participants
Start Date 2024-11-05
Primary Completion 2030-04-30 (estimated)
Study Completion 2030-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-02